Targets › SLC47A1
1 program from 1 company in 3 trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Gastroenterology, Oncology, Other; next expected readout Oct 2027.
Multidrug efflux pump that functions as a H(+)/organic cation antiporter. Plays a physiological role in the excretion of cationic compounds including endogenous metabolites, drugs, toxins through the kidney and liver, into urine and bile respectively. (UniProt, Q96FL8)
Open in Phaseline: the race on SLC47A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bayer | BAY 2927088 (Sevabertinib) MATE1 and MATE2-K transporter inhibitor | ERBB2, SLC47A1, SLC47A2 | Phase 3 | Advanced Non-small Cell Lung Cancer, HER2 Mutation; Advanced Solid Tumors; Healthy Participants | Oct 2027 |
Advanced Non-small Cell Lung Cancer, HER2 Mutation (1) Advanced Solid Tumors (1) Healthy Participants (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.